Scarica l'app Stockscreener
3.36
8.74%
0.27
Dopo l'orario di chiusura:
3.28
-0.08
-2.38%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SANA Giù?
Forum
Previsione
Precedente Chiudi:
$3.09
Aprire:
$3.19
Volume 24 ore:
4.55M
Relative Volume:
1.54
Capitalizzazione di mercato:
$896.67M
Reddito:
-
Utile/perdita netta:
$-252.18M
Rapporto P/E:
-3.1698
EPS:
-1.06
Flusso di cassa netto:
$-185.29M
1 W Prestazione:
+6.67%
1M Prestazione:
-12.73%
6M Prestazione:
+4.35%
1 anno Prestazione:
+26.55%
Intervallo 1D:
$3.18
$3.38
Intervallo di 1 settimana:
$3.00
$3.48
Portata 52W:
$1.26
$6.55
Sana Biotechnology Inc Stock (SANA) Company Profile
Nome
Sana Biotechnology Inc
Settore
Industria
Telefono
(206) 701-7914
Indirizzo
188 EAST BLAINE STREET, SUITE 350, SEATTLE
Compare SANA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
3.36 | 896.67M | 0 | -252.18M | -185.29M | -1.06 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-24 | Iniziato | Wedbush | Outperform |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-03-18 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-03-14 | Iniziato | Jefferies | Buy |
| 2025-01-08 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-11-05 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-06-26 | Iniziato | Rodman & Renshaw | Buy |
| 2024-01-16 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-09-25 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-09-05 | Iniziato | Citigroup | Buy |
| 2023-08-14 | Iniziato | TD Cowen | Market Perform |
| 2023-05-02 | Iniziato | H.C. Wainwright | Neutral |
| 2021-03-01 | Iniziato | BofA Securities | Buy |
| 2021-03-01 | Iniziato | Goldman | Neutral |
| 2021-03-01 | Iniziato | JP Morgan | Neutral |
| 2021-03-01 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Sana Biotechnology Inc Borsa (SANA) Ultime notizie
Sana Biotechnology reports 14-month data on diabetes cell therapy - Investing.com India
Sana Biotechnology reports 14-month data on diabetes cell therapy By Investing.com - Investing.com Canada
Morgan Stanley Maintains Overweight on Sana Biotechnology, Inc. (SANA) March 2026 - Meyka
Morgan Stanley reiterates Sana Biotechnology stock rating on diabetes data By Investing.com - Investing.com Canada
Transplanted insulin cells work 14 months without immune drugs in T1D patient - Stock Titan
Earnings Report: Will Sana Biotechnology Inc benefit from sector rotation2026 Earnings Surprises & Consistent Return Investment Signals - baoquankhu1.vn
SANA: Hypoimmune and in vivo CAR T platforms advance toward clinical trials, with key data expected soon - TradingView
Sana (SANA) CEO Steve Harr vests RSUs and uses 24,345 shares for tax - Stock Titan
VIX Spike: Can Sana Biotechnology Inc be the next market leader2026 Chart Watch & Comprehensive Market Scan Reports - baoquankhu1.vn
Sana Biotechnology (SANA) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Sana Diabetes Data And Funding Moves Reframe Risk For NasdaqGS SANA Investors - Sahm
Aug Drivers: Is Sana Biotechnology Inc attractive at current valuation2025 Market Trends & Short-Term High Return Ideas - baoquankhu1.vn
Sana Biotechnology (SANA) CEO granted 200,000 RSUs and 900,000 stock options - Stock Titan
TD Cowen reiterates Buy rating on Sana Biotechnology stock By Investing.com - Investing.com Canada
TD Cowen reiterates Buy rating on Sana Biotechnology stock - Investing.com UK
Q1 EPS Estimate for Sana Biotechnology Lowered by Analyst - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Stock Price Down 9.7% After Analyst Downgrade - MarketBeat
What is HC Wainwright's Forecast for SANA FY2030 Earnings? - MarketBeat
Seattle InnoCajal raises $96M I Layoffs at Sana - The Business Journals
Sana Biotechnology (NASDAQ:SANA) Cut to Hold at Zacks Research - MarketBeat
Citizens reiterates Sana Biotechnology stock rating on pipeline progress By Investing.com - Investing.com Nigeria
AI Adoption Exposes Sana Biotechnology to Rising Data, Compliance, and Reputational Risks - TipRanks
Sana Biotechnology (SANA) officer exercises RSUs, uses 491 shares for taxes - Stock Titan
Sana Biotechnology Diabetes Data And CAR T Plans Shape Pipeline Outlook - simplywall.st
Sana Biotechnology (SANA) Q4 2025 Financial Results: Net Loss and Analyst OutlookNews and Statistics - IndexBox
Sana Biotechnology (NASDAQ:SANA) Price Target Lowered to $7.00 at HC Wainwright - MarketBeat
Sana Biotech's Q4 Net Loss Expands; Plans To Submit IND For SC451 In 2026; Stock Down - Nasdaq
Sana Biotechnology files for mixed shelf size not disclosedSEC filing - marketscreener.com
Sana Biotechnology Files For Mixed Shelf Size Not DisclosedSEC Filing - TradingView
Sana Biotechnology (NASDAQ: SANA) files ATM to raise up to $150M with TD Cowen - Stock Titan
Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates - Bitget
Sana: Overview of Fourth Quarter Financial Results - Bitget
Sana Biotechnology Updates ATM Program to Support Development - TipRanks
Earnings Flash (SANA) Sana Biotechnology, Inc. Posts Q4 Adjusted Loss $0.16 per Share, vs. FactSet Est of $-0.14 - marketscreener.com
Going concern risk and focused pipeline at Sana Biotechnology (NASDAQ: SANA) - Stock Titan
Sana Biotechnology (NASDAQ: SANA) sets $150.0 million ATM program - Stock Titan
SANA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Sana Biotechnology, Inc. (SANA): A Bull Case Theory - Yahoo Finance
SANA SEC FilingsSana Biotechnology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Sana Biotechnology (SANA) Stock Analysis: Exploring a Potential 104% Upside with Innovative Cell Therapies - DirectorsTalk Interviews
Sana Biotechnology, Inc. (NASDAQ:SANA) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Sana Biotechnology (SANA) Appoints Industry Veteran Brian Piper as New CFO - Yahoo Finance
Assessing Sana Biotechnology (SANA) Valuation After The Appointment Of A New CFO - Yahoo Finance
Assessing Sana Biotechnology (SANA) Valuation After Recent Share Price Momentum - simplywall.st
Sana Biotechnology to Present at March 2026 Investor Conferences - GlobeNewswire
Is Sana Biotechnology Inc a stock for growth or value investorsTreasury Yields & Daily Oversold Bounce Ideas - baoquankhu1.vn
Genomics Stocks That Deserve a Place in Your Portfolio in 2026 - TradingView
Sana Biotechnology (SANA) CFO awarded new RSUs and 900,000 options - Stock Titan
Sana Biotechnology Names Brian Piper as New CFO - The Globe and Mail
All You Need to Know About Sana (SANA) Rating Upgrade to Buy - MSN
Sana Biotechnology stock falls after naming new CFO By Investing.com - Investing.com South Africa
Sana Biotechnology Inc Azioni (SANA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):